Cargando…
Guillain-Barre Syndrome Secondary to the Use of Dabrafenib and Trametinib for the Treatment of Advanced Thyroid Carcinoma
BRAF V600E mutation in thyroid malignancies is associated with an aggressive phenotype with more rapid tumor growth and higher mortality. V600E is a driver mutation in the BRAF proto-oncogene, where valine (V) is substituted by glutamic acid (E) at amino acid 600. New chemotherapeutic agents targeti...
Autores principales: | Batra, Jaskaran, Ankireddypalli, Anvitha, Kanugula, Ashok K, Gorle, Swathi, Kaur, Jasleen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937682/ https://www.ncbi.nlm.nih.gov/pubmed/36819948 http://dx.doi.org/10.7759/cureus.35069 |
Ejemplares similares
-
Thyrotoxic Periodic Paralysis With Severe Hypokalemia Precipitated by Acute Alcohol Intoxication in a Patient With Graves’ Disease
por: Batra, Jaskaran, et al.
Publicado: (2023) -
Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate
por: Batra, Jaskaran, et al.
Publicado: (2023) -
Progesterone Hypersensitivity Induced by Exogenous Progesterone Exposure
por: Dhaliwal, Gurnoor, et al.
Publicado: (2023) -
Papillary Thyroid Cancer Differentiating Into Anaplastic Carcinoma With Near-Complete Response to Targeted Dabrafenib/Trametinib Combination Therapy
por: Kulkarni, Pruthali, et al.
Publicado: (2021) -
Renin-Angiotensin System: Updated Understanding and Role in Physiological and Pathophysiological States
por: Kanugula, Ashok Kumar, et al.
Publicado: (2023)